Longeveron ELPIS II misses HLHS primary endpoint; strategic review starts
Longeveron said its ELPIS II trial in HLHS did not meet the primary RVEF endpoint (LS mean diff −0.7 pts; p=0.8336) and has begun a review of options to maximize shareholder value, including cash conservation. Safety was generally consistent with prior studies.
Longeveron said ELPIS II in HLHS missed the primary RVEF endpoint, with an LS mean difference of −0.7 points and p=0.8336. The company also said it has started a review of all options to maximize shareholder value, including cash conservation. Safety was generally consistent with prior studies.